Why Ozempic May Not Work for Everyone: SDRC Investigator Anna Gloyn and Colleagues Uncover a Genetic Resistance to GLP-1 Drugs

A decade-long study finds that roughly 1 in 10 people carry genetic variants that may blunt the blood sugar-lowering effects of widely used diabetes medications — raising new questions about precision medicine in diabetes care. Read more...

Next
Next

A Python-Derived Molecule Called pTOS Could Point to New Weight-Loss Pathways